Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Hospital del Mar
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital del Mar (13)
2024
-
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Clinical Genitourinary Cancer, Vol. 22, Núm. 5
-
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
ESMO Open, Vol. 9, Núm. 9
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
2021
-
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2019
2018
-
Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes
Clinical Cancer Research, Vol. 24, Núm. 24, pp. 6115-6124
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Targeting NK-cell checkpoints for cancer immunotherapy
Current Opinion in Immunology, Vol. 45, pp. 73-81
2014
2011
2010
-
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)
The Lancet Oncology, Vol. 11, Núm. 4, pp. 350-357